Lab News
Demetrios Braddock, MD, PhD, Associate Professor of Pathology, is among 10 physician-scientists named as recipients of the Harrington Discovery Institute 2024 Scholar-Innovator Award.
- March 25, 2024
The Yale Pathology Research in Progress series provides students with feedback that helps improve their research projects and presentations.
- January 25, 2023Source: Yale News
Yale faculty members are translating their research into new technologies and treatments for disease. Yale Ventures helps them along the way.
- October 18, 2022
Two Yale Pathology professors were among 12 faculty members honored with 2022 Yale Faculty Innovation Awards, which recognize the significant contributions of Yale faculty who develop new technologies and launch startups that address global challenges.
- July 11, 2022
The Braddock Lab in the Department of Pathology at Yale School of Medicine has found that mammalian bone mass is regulated by catalysis independent ENPP1 protein signaling pathways.
- March 23, 2022
The Braddock Lab in the Department of Pathology at Yale School of Medicine has found that a common disease of aging, which induces spinal stiffness and rigidity, is associated with haploinsufficiency of ENPP1 (heterozygous ENPP1 deficiency).
- September 14, 2021
The Yale School of Medicine, Department of Pathology, is seeking a highly motivated postdoctoral associate to work in the Braddock lab, which investigates severe unmet medical illness through the study of Rare Diseases with a focus on dysregulated mineralization of the vasculature and the skeleton.
- May 21, 2021
The Blavatnik Fund for Innovation at Yale, made possible by a generous grant from the Blavatnik Family Foundation, supports Yale faculty in the commercialization of applied research and technology in the life sciences.
- May 09, 2019Source: Patch
Governor Ned Lamont, yesterday joined hundreds of Yale faculty, students, entrepreneurs and investors at the 2019 Yale Innovation Summit and solidified his commitment to support innovation in the New Haven Area.
- April 10, 2019Source: Business Wire
A biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as the Company’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round. Inozyme Pharma is a biotechnology company committed to developing novel medicines for the treatment of rare mineralization disorders. Inozyme Pharma was founded in 2017 by Joseph Schlessinger Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc., MBA. The Company licensed technology from Yale University, developed in the laboratory of Dr. Braddock.